Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.60 |
| ▸ | HTR1A | P08908 | 6/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 4/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31615878 | 0.98 | SLC18A3 (0.66) | SLC18A3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Trifluoroacetic Acid SCHEMBL381669 | 0.87 | SLC18A3 (0.51) | SLC18A3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19322267 | 0.86 | KDM1A (0.57) | SLC18A3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3970721 | 0.86 | KDM1A (0.57) | SLC18A3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3040992 | 0.84 | SLC6A2 (0.62) | SLC18A3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8492021 | 0.83 | SLC18A3 (0.59) | SLC18A3SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26154062 | 0.82 | KDM1A (0.53) | SLC6A2SLC6A4SLC6A3LTA4HKDM1A | |
| SCHEMBL8710331 | 0.82 | KDM1A (0.53) | SLC6A2SLC6A4SLC6A3LTA4HKDM1A | |
| Benzene SCHEMBL28128069 | 0.82 | SLC18A3 (1.00) | SLC18A3SIGMAR1HTR2C | |
| SCHEMBL4574 | 0.82 | SLC18A3 (1.00) | SLC18A3SIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2024-03-12 | — | — | US | claimed |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2022-02-17 | — | — | US | claimed |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2021-04-20 | — | — | US | claimed |
| US-20200253958-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2020-08-13 | — | — | US | claimed |
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4028403-B1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-11-22 | — | — | EP | disclosed |
| US-11814375-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4028403-A1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| CN-114269755-A | 4,4A,5,7,8, 8A-hexapyrido [4,3-B ] [1,4] oxazin-3-one compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2022-02-17 | — | — | US | disclosed |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210094943-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| CN-1281433-A | Hydroxamic acid derivatives as matrix metalloproteinase (MMP) inhibitors | PFIZER LTD (US) | 2001-01-24 | — | — | CN | disclosed |
| US-6048876-A | ANTICONVULSANTS; ANTIEPILEPIC AGENT | SUNTORY LIMITED (JP) | 2000-04-11 | — | — | US | disclosed |
| CN-1246110-A | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and drugs containing the same | SUNTORY LTD (JP) | 2000-03-01 | — | — | CN | disclosed |
| EP-0958280-A1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999023072-A1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1999-05-14 | — | — | WO | disclosed |
| US-5723475-A | Arylpiperidine and arylpiperazine derivatives and medicament containing the same | SUNTORY LIMITED (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0757986-A1 | ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0755923-A1 | AMELIORANT OR REMEDY FOR SYMPTOMS CAUSED BY ISCHEMIC DISEASES AND COMPOUNDS USEFUL THEREFOR | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253958-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PCSK9, LDLR, PCSK7 | SLC18A3 4317/4885SIGMAR1 2304/4885SLC6A2 4641/4885 |
| US-11814375-B2 | Heterocyclic compounds | CYP1B1, CYP1A1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC18A3 4359/4885SIGMAR1 1057/4885SLC6A2 4473/4885 |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PCSK9, LDLR, PCSK7 | SLC18A3 4317/4885SIGMAR1 2304/4885SLC6A2 4641/4885 |
| US-20210094943-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | SLC18A3 4396/4885SIGMAR1 961/4885SLC6A2 4533/4885 |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | SLC18A3 4317/4885SIGMAR1 2304/4885SLC6A2 4641/4885 |
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | SLC18A3 4317/4885SIGMAR1 2304/4885SLC6A2 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.